YS Bioventure Manage

The office concentrates on pre-seed through Series A biotechnology and healthcare companies. It prefers entering at the translational science stage, where academic breakthroughs are being formed into startups. The permanent-capital structure allows it to hold positions through later clinical phases without pressure to exit.

Sourcing relies heavily on principal-to-principal relationships with academic technology transfer offices, incubators linked to major research hospitals, and a tight network of repeat co-investing venture firms. Because the office does not market itself to bankers or placement agents, much of its pipeline comes through founder referrals and scientific advisory board connections.

The office regularly co-invests alongside specialist healthcare venture capital funds. It is known to take pro-rata follow-on rights in companies where it led or co-led early rounds. Its permanent-capital nature makes it a desirable syndicate partner for firms seeking aligned, long-term support in capital-intensive clinical-stage companies.

The primary geographic focus is North America, particularly the biotechnology clusters in Boston, San Francisco, and San Diego. The office has also selectively participated in rounds for companies based in Europe and Asia-Pacific when the science and intellectual property align with its thesis.